alea-institute/kl3m-data-sample-004-shuffled huggingface dataset:
Exhibit
32.3





CERTIFICATIONS








Pursuant
to 18 U.S.C. § 1350, each of the undersigned officers of Discovery Laboratories,
Inc. (the “Company”) hereby certifies that our Amendment No. 2 on Form 10-K/A
for the year ended December 31, 2009 (the “Report”) fully complies with the
requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934,
and that the information contained in the Report fairly presents, in all
material respects, the financial condition and results of operations of the
Company.








Date:
November 12, 2010


/s/
      W. Thomas AmickW.
      Thomas AmickChairman
      of the Board
                  and
      Chief Executive Officer
  /s/
      John G. CooperJohn
      G. CooperPresident
      and Chief Financial Officer


A signed
original of this written statement required by Section 906 of the Sarbanes-Oxley
Act of 2002 has been provided to the Company and will be retained by the Company
and furnished to the SEC or its staff upon request.




This
certification is being furnished pursuant to Section 906 of the Sarbanes-Oxley
Act of 2002 and shall not be deemed “filed” for purposes of Section 18 of the
Securities Exchange Act of 1934, or otherwise subject to the liability of that
section.  This certification will not be deemed to be incorporated by
reference into any filing under the Securities Act of 1933 or the Securities
Exchange Act of 1934.
#### § 50.50 IRB duties.

In addition to other responsibilities assigned to IRBs under this part and part 56 of this chapter, each IRB must review clinical investigations involving children as subjects covered by this subpart D and approve only those clinical investigations that satisfy the criteria described in § 50.51, § 50.52, or § 50.53 and the conditions of all other applicable sections of this subpart D.
§ 358.503 Definitions. As used in this subpart: ( a ) *Corn and callus remover drug product.* A topical agent used for the removal of corns and calluses.
( b ) *Collodion-like vehicle.* A solution containing pyroxylin (nitrocellulose) in an appropriate nonaqueous solvent that leaves a transparent cohesive film when applied to the skin in a thin layer.
( c ) *Plaster vehicle.* A fabric, plastic, or other suitable backing material in which medication is usually incorporated for topical application to the skin.
§ 58.210 Actions upon disqualification. ( a ) Once a testing facility has been disqualified, each application for a research or marketing permit, whether approved or not, containing or relying upon any nonclinical laboratory study conducted by the disqualified testing facility may be examined to determine whether such study was or would be essential to a decision. If it is determined that a study was or would be essential, the Food and Drug Administration shall also determine whether the study is acceptable, notwithstanding the disqualification of the facility. Any study done by a testing facility before or after disqualification may be presumed to be unacceptable, and the person relying on the study may be required to establish that the study was not affected by the circumstances that led to the disqualification, e.g., by submitting validating information. If the study is then determined to be unacceptable, such data will be eliminated from consideration in support of the application; and such elimination may serve as new information justifying the termination or withdrawal of approval of the application.
( b ) No nonclinical laboratory study begun by a testing facility after the date of the facility's disqualification shall be considered in support of any application for a research or marketing permit, unless the facility has been reinstated under § 58.219. The determination that a study may not be considered in support of an application for a research or marketing permit does not, however, relieve the applicant for such a permit of any obligation under any other applicable regulation to submit the results of the study to the Food and Drug Administration.
[43 FR 60013, Dec. 22, 1978, as amended at 59 FR 13200, Mar. 21, 1994]
<TABLE> <S> <C>

<ARTICLE> 5
<LEGEND>
This schedule contains summary financial information extracted from the
Company's consolidated financial statements included in form 10-K and is
qualified in its entirety by reference to such financial statements.
</LEGEND>

<S>                             <C>
<PERIOD-TYPE>                   YEAR
<FISCAL-YEAR-END>                          JUN-30-1999
<PERIOD-END>                               JUN-30-1999
<CASH>                                       5,949,000
<SECURITIES>                                         0
<RECEIVABLES>                                1,591,000
<ALLOWANCES>                                  (15,000)
<INVENTORY>                                  4,909,000
<CURRENT-ASSETS>                            12,699,000
<PP&E>                                       6,475,000
<DEPRECIATION>                               4,101,000
<TOTAL-ASSETS>                              16,097,000
<CURRENT-LIABILITIES>                        8,050,000
<BONDS>                                              0
<PREFERRED-MANDATORY>                                0
<PREFERRED>                                  4,948,000
<COMMON>                                    19,993,000
<OTHER-SE>                                (16,894,000)
<TOTAL-LIABILITY-AND-EQUITY>                16,097,000
<SALES>                                     13,972,000
<TOTAL-REVENUES>                            13,972,000
<CGS>                                        8,253,000
<TOTAL-COSTS>                               12,967,000
<OTHER-EXPENSES>                                     0
<LOSS-PROVISION>                                     0
<INTEREST-EXPENSE>                           (260,000)
<INCOME-PRETAX>                            (6,988,000)
<INCOME-TAX>                                         0
<INCOME-CONTINUING>                        (6,988,000)
<DISCONTINUED>                                       0
<EXTRAORDINARY>                                      0
<CHANGES>                                            0
<NET-INCOME>                               (6,988,000)
<EPS-BASIC>                                     (0.79)
<EPS-DILUTED>                                   (0.79)


</TABLE>
- All
            - Title
            - Author
            - Subject
            - Date
            - Full-Text

            -                              Explore                            ******                - Educational Resources
              - Archival Collections
              -                                      Themes                                    ******                  - Economic Data
                - Federal Reserve
                - View all 
              - Timelines 
            -                              Browse                            ******                - Titles
              - Authors
              - Subjects
              - Dates 
            -                              About                            ******                - About FRASER
              - FAQ
              - Contact Us
              -                                      FRASER API                                    ******                  - REST API
                - OAI-PMH 
            - Inside FRASER Blog

            - **

Home                 > Browse by Title > Materials Prepared in Connection with the Study of Employment, Growth, and Price Levels for Consideration by the Joint Economic Committee, Congress of the United States

              																								United States. Congress. Joint Economic Committee, 1956-					 and 	Eighty-Sixth Congress, 1959-1961.						"Study Paper No. 16 : International Effects of U.S. Economic Policy" in *Materials Prepared in Connection with the Study of Employment, Growth, and Price Levels for Consideration by the Joint Economic Committee, Congress of the United States*			(January 25, 1960).						https://fraser.stlouisfed.org/title/1244/item/3641, accessed on September 26, 2024.	    

        - **FRASER**
        - About
        - FAQ
        - Legal and Privacy
        - FRASER API

          -                              @FedFRASER 
          - ** Contact Us
          -  **  What's New  
          -  **  Inside FRASER
<TABLE> <S> <C>

<PAGE>
<ARTICLE> 5
<MULTIPLIER> 1,000

<S>                             <C>
<PERIOD-TYPE>                   3-MOS
<FISCAL-YEAR-END>                          DEC-31-2000
<PERIOD-END>                               JUL-02-2000
<CASH>                                           2,246
<SECURITIES>                                         0
<RECEIVABLES>                                   13,783
<ALLOWANCES>                                     (863)
<INVENTORY>                                     11,297
<CURRENT-ASSETS>                                 1,928
<PP&E>                                          83,064
<DEPRECIATION>                                (33,302)
<TOTAL-ASSETS>                                  80,706
<CURRENT-LIABILITIES>                           47,456
<BONDS>                                              0
<PREFERRED-MANDATORY>                                0
<PREFERRED>                                          0
<COMMON>                                             8
<OTHER-SE>                                      10,564
<TOTAL-LIABILITY-AND-EQUITY>                    80,706
<SALES>                                         20,928
<TOTAL-REVENUES>                                20,928
<CGS>                                           16,922
<TOTAL-COSTS>                                   22,004
<OTHER-EXPENSES>                                     0
<LOSS-PROVISION>                                     0
<INTEREST-EXPENSE>                               (530)
<INCOME-PRETAX>                                (1,606)
<INCOME-TAX>                                      (41)
<INCOME-CONTINUING>                            (1,647)
<DISCONTINUED>                                       0
<EXTRAORDINARY>                                      0
<CHANGES>                                            0
<NET-INCOME>                                   (1,647)
<EPS-BASIC>                                     (0.22)
<EPS-DILUTED>                                   (0.22)


</TABLE>
Josh Kendrick FedEx Express - AOD Telephone 901.224.0802

Managing Director 3131 Democrat Rd. Mobile 901.579.9018

Flight Technical & Reg. Compliance Building C, Suite 171 Fax 901.224.5516

Memphis, TN 38118

December 4, 2015

Mr. Hal Medling

Supervisory Principal Operations Inspector

FAA/FedEx Certificate Management Office

2847 Business Park Drive, Building J

Memphis, TN 38118

Subject: Letter of Intent for Issuance of Exemption No. 12555 from 91.227 of Title 14, Code of 

Federal Regulations 

Dear Inspector Medling:

FedEx Express submits this Letter of Intent for Issuance of Exemption No. 12555 from 14 CFR 91.227

IAW Regulatory Docket No. FAA-2015-0971. This exemption pertains to the 2020 mandate for ADS-B 

OUT positioning source accuracy requirements in the National Airspace System. 

Attached with this Letter of Intent is information pertaining to completing Exemption No. 12555. 

 

The contents are organized as follows: 

Chapter 1 - Letter of Intent, Exemption No. 12555

Chapter 2 - Regulatory Docket No. FAA-2015-0971

Chapter 3 - ADS-B Exemption Petition Diagram

Chapter 4 - Upgrade Plan Template.xlsx

We understand the Upgrade Plan process will require close coordination between your staff and mine. 

We stand ready to resolve any issues or concerns that you find need additional attention or clarification.

My point of contact for this project is Larry Hills, System Technical Pilot, (901) 224-5170. 

Sincerely,

Josh Kendrick

Managing Director 

Flight Technical & Regulatory Compliance

FedEx Express – Air Operations Division

JBK/shd/lch
UNPUBLISHED

UNITED STATES COURT OF APPEALS

FOR THE FOURTH CIRCUIT

No. 01-6734

NATHANIEL EPPS,

Petitioner - Appellant,

versus

RONALD J. ANGELONE, Director of the Virginia

Department of Corrections,

Respondent - Appellee.

Appeal from the United States District Court for the Eastern District of Virginia, at Richmond. Robert E. Payne, District Judge.

(CA-00-716)

Submitted: September 18, 2001 Decided: October 9, 2001

Before MICHAEL and GREGORY, Circuit Judges, and HAMILTON, Senior

Circuit Judge.

Dismissed by unpublished per curiam opinion.

Nathaniel Epps, Appellant Pro Se. Thomas Drummond Bagwell, Assistant Attorney General, Richmond, Virginia, for Appellee.

Unpublished opinions are not binding precedent in this circuit.

See Local Rule 36(c).
2

PER CURIAM:

Nathaniel Epps appeals the district court’s order denying his

28 U.S.C.A. § 2254 (West 1994 & Supp. 2001) petition as untimely

filed. We have reviewed the record, the district court’s opinion,

and Epps’ informal appellate brief. Because Epps failed to challenge on appeal the basis for the district court’s ruling, he has

not preserved any issue for our review. 4th Cir. R. 34(b). In

addition, it is clear that the district court’s conclusion that

Epps’ petition was untimely is correct. Accordingly, we deny a

certificate of appealability and dismiss the appeal. We dispense

with oral argument because the facts and legal contentions are

adequately presented in the materials before the court and argument

would not aid the decisional process.

DISMISSED
Exhibit








EX-10.1





April 24, 2017
Denise R. Cade
c/o IDEX Corporation
1925 West Field Court, Suite 200, 
Lake Forest, IL  60045-4824


Re:  Amendment of Letter Agreement Dated September 24, 2015


Dear Denise:


This letter agreement will confirm an amendment to the letter agreement (“Letter Agreement”) dated September 24, 2015 between you and IDEX Corporation (“IDEX”).  


The Letter Agreement is amended by deleting the twelfth bullet point provisions, which provide for payments due to you if your employment with IDEX is terminated without cause, and such provisions will no longer be in effect.  


You and IDEX hereby agree to the addition of the following provisions to the Letter Agreement:


		
	•
	If, in the future, your employment with IDEX Corporation is terminated, without cause (“cause” defined as willful misconduct or fraudulent behavior), IDEX will pay you twelve (12) months base salary at the then current monthly base rate plus your targeted annual incentive bonus in exchange for you signing, and not revoking, an IDEX-standard Severance Agreement & General Release Agreement.  These payments are subject to tax withholdings and deductions.  Such benefit will not be applicable in the event of your voluntary termination.  




Please indicate your acceptance of these provisions below.


Best regards, 


/s/ JEFFREY D. BUCKLEW


Jeffrey D. Bucklew
SVP, Chief Human Resources Officer 
IDEX Corporation 
1925 West Field Court
Suite 200
Lake Forest, IL 60045


	
			
	April 24, 2017
	 
	/s/ DENISE R. CADE

	Date
	 
	Acceptance of Provisions

	 
	 
	Denise R. Cade
# *\c W\ Ww twv ) RECEIVED IN W. fc\a\ JX^D^^W. ©0UBTOFCRIMINALAPPEALS 

# "YVWWrtft ^^\S\u^\©v\ ) JUN16 2015 j Ab@IAeosta,Cterf* 

# (^-OV\V>-vQ FILED IN COURTOFCRIMINALAPPEALS 

## W t\A^ JUN 19 2075 Abel Acosta, Clerk 

# x^saVWssu: \jO^>vjW \\Vx_\^ X\csV ^K^S- W^ fc^ \N^o<x

# ^YvNd\V> ^o^\ovC\vvvn \As ssAoXcmX vtVCNAV^ c-J\\w\f\v»v



# VaN\>T^ T^^00\r\\i^ \rv C^,VLC<JV\L>^ Atj^ \VvOvXM^^cVsj^ft.



# °W5 S^wr ^

CO

# ^3urV\V\CV)W cX S&jrvAO^.



# CjDvxrV ^^AntA^cwX Kfc&su\s X>V"Wu^ ^^.\>^ \V^;

0\ V\rV^\s"^M^^\X\A\VrV Cxjvv^ ^vx\<\<V\*^X \^\\J\rv<K



# N^yL^oAuK ^v>v -^W. ^^ Wax At^Wxvio^ ^VS'
^CS -^h W

0>A

# fc^V-*" \
Law Offices ofAlex B. Eyssen, pllc Post Office Box 3321 Abilene, Texas 79604 www.eyssenlaw.com

Alex B.Eyssen Telephone (325) 267-6030 Alex@eyssenlaw.com Facsimile (325)267-6031 August 28, 2012
Daniel Dominguez #1355966 Nathaniel Neal Unit 9055 Spur 5.91 Amarillo, Texas 19107 Re: Cause No. 13674-B; State ofTexas vs. Daniel Dominguez Dear Mr. Dominguez: I am in receipt ofyour letter dated August 20, 2012. Please be advised that it is not my custom or typical practice to respond to each and every letter I receive from my clients. Rather, I generally respond if and when there is an update. The issue we are facing is (l) whether any DNA evidence exists that is in possession of the State and (2) whether any DNA evidence exists from another case. First, I have requested an official response from the District Attorney. I have been told that the District Attorney is preparing a response to our request to determine whether any DNA evidence was taken, preserved, and available for testing. I expect a written response any day. In speaking with the Assistant 

### District Attorney regarding this matter, I anticipate the response will be to the effect that no DNAevidence exists. As soon I as receive a response, I will let you know. Given that over 60 days has passed for the State 

### to respond, I will file a Motion requiring the State to respond ifnone is received within the next couple of days. Second, I have requested that I be permitted to inspect the file related to Cause 5034-CX. That case file is considered a "closed" file. Thus, I have to obtain permission from the S26th District Court in order to 

### inspect said file. Prior to being permitted to review the file, the District Judge first has to review the file and then contact the parties involved to allow them the opportunity to object. This includes the "victim". The Judge will let meknow if and when I can inspect the file. I fully anticipate the Court will allow me to inspect the file, however, ifaccess is denied, then we can discuss our other remedies to gain access to the information contained therein. In addition, I have obtained and reviewed your entire Court file regarding Cause No. 13674-B. For your convenience, I have enclosed a copy herein.

Abilene Office Anson Office 802 Mulberry 311N. Commercial Abilene Texas 79601 Anson, Texas 79501
§ 582.1751 Sodium citrate. ( a ) *Product.* Sodium citrate.
( b ) *Conditions of use.* This substance is generally recognized as safe when used in accordance with good manufacturing or feeding practice.
Exhibit 31.1


                                 CERTIFICATIONS
                                 --------------

I, Allan D. Keel, certify that:

     1.   I have reviewed this Quarterly Report on Form 10-Q/A of Crimson
          Exploration Inc.;

     2.   Based on my knowledge, this report does not contain any untrue
          statement of a material fact or omit to state a material fact
          necessary to make the statements made, in light of the circumstances
          under which such statements were made, not misleading with respect to
          the period covered by this report;

     3.   The registrant's other certifying officer(s) and I are responsible for
          establishing and maintaining disclosure controls and procedures (as
          defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) for the
          registrant and have:

          (a) Designed such disclosure controls and procedures, or caused such
          disclosure controls and procedures to be designed under our
          supervision, to ensure that material information relating to the
          registrant, including its consolidated subsidiaries, is made known to
          us by others within those entities, particularly during the period in
          which this report is being prepared;

          (b) Evaluated the effectiveness of the registrant's disclosure
          controls and procedures and presented in this report our conclusions
          about the effectiveness of the disclosure controls and procedures, as
          of the end of the period covered by this report based on such
          evaluation; and

          (c) Disclosed in this report any change in the registrant's internal
          control over financial reporting that occurred during the registrant's
          most recent fiscal quarter (the registrant's fourth fiscal quarter in
          the case of an annual report) that has materially affected, or is
          reasonably likely to materially affect, the registrant's internal
          control over financial reporting; and

     4.   The registrant's other certifying officer(s) and I have disclosed,
          based on our most recent evaluation of internal control over financial
          reporting, to the registrant's auditors and the audit committee of the
          registrant's board of directors (or persons performing the equivalent
          functions):

          (a) All significant deficiencies and material weaknesses in the design
          or operation of internal control over financial reporting which are
          reasonably likely to adversely affect the registrant's ability to
          record, process, summarize and report financial information; and

          (b) Any fraud, whether or not material, that involves management or
          other employees who have a significant role in the registrant's
          internal control over financial reporting.

Date: July 17, 2006



/s/  Allan D. Keel
-------------------------------
Allan D. Keel
President and
Chief Executive Officer
#### § 558.612 Tiamulin.

(a) *Specifications.* Type A article containing 363.2 grams of tiamulin hydrogen fumarate per pound.

(b) *Sponsor.* See No. 058198 in § 510.600(c) of this chapter.

(c) *Related tolerances.* See § 556.732 of this chapter.

(d) *Special considerations.*

(1) Swine being treated with tiamulin should not have access to feeds containing polyether ionophores (e.g., lasalocid, monensin, narasin, salinomycin, or semduramycin) as adverse reactions may occur. If signs of toxicity occur, discontinue use.

(2) The effects of tiamulin on swine reproductive performance, pregnancy, and lactation have not been determined.

(3) Use as sole source of tiamulin.

(e) *Conditions of use* —

(1) *Swine.* It is used as follows:

| Tiamulin hydrogen fumarate in grams per ton | Combination in grams per ton | Indications for use | Limitations | Sponsor |
| --- | --- | --- | --- | --- |
| (i) 35 | | 1. For control of swine dysentery associated with *Brachyspira* (formerly *Serpulina* or *Treponema*) *hyodysenteriae* susceptible to tiamulin | Feed continuously as sole ration on premises with a history of swine dysentery but where signs of disease have not yet occurred or following approved treatment of disease. Withdraw 2 days before slaughter | 058198 |
| | | 2. For control of porcine proliferative enteropathies (ileitis) associated with *Lawsonia intracellularis* | Feed continuously as the sole ration for not less than 10 days. Withdraw 2 days before slaughter | 058198 |
| (ii) 200 | | For treatment of swine dysentery associated with *Brachyspira* (formerly *Serpulina* or *Treponema*) *hyodysenteriae* susceptible to tiamulin | Feed continuously as the sole feed for 14 consecutive days. Withdraw feed 7 days before slaughter | 058198 |

(2) Tiamulin may also be used in combination with chlortetracycline as in § 558.128.

[67 FR 7268, Feb. 19, 2002, as amended at 69 FR 62407, Oct. 26, 2004; 70 FR 75018, Dec. 19, 2005; 74 FR 6, Jan. 2, 2009; 77 FR 24139, Apr. 23, 2012; 79 FR 13546, Mar. 11, 2014. Redesignated and amended at 80 FR 13232, Mar. 13, 2015; 81 FR 95015, Dec. 27, 2016; 86 FR 14827, Mar. 19, 2021]